Asmaa A. Khalifa, PhD (1), Mai El-Sayed Ghoneim, MS(2), Bassma Mahmoud Ali, MS(3)
  1. Department of Pharmacology and therapeutics, Faculty of Pharmacy and drug manufacturing, Pharos University, Alexandria, Egypt
  2. Department of Pharmacology and toxicology, faculty of Pharmacy, University of Sadat City , Menofia, Egypt
  3. Department of Special Chemistry, Arab Academy for Sciences and Technology and Maritime Transport, Alexandria, Egypt
Contact details of Corresponding author :
Name: Asmaa Ahmed Khalifa
Email : asmaa.khalifa@pua.edu.eg
Phone number: +0201274832271
By the end of 2019, some local health authorities reported significant number of patients with unkown cause pneumonia. However, all patients have a common factor that they where in a market in Wuhan, China. On January 2020, the WHO announced that COVID-19 caused by severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) is a pandemic disease (Sanders et al., 2020). This virus belongs to coronaviruses single-stranded RNA family which can infect both animals and humans. Till now there is no standard treatment , however, massive research efforts were made to manage this novel virus. To present the therapeutic approches that are currntly avilable, the understanding of the pathophysiology of the virus is a must.